BioXcel Therapeutics Inc (BTAI)
2.07
-0.02
(-0.96%)
USD |
NASDAQ |
May 17, 16:00
2.07
0.00 (0.00%)
After-Hours: 20:00
BioXcel Therapeutics Revenue (Quarterly): 0.582M for March 31, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 0.582M |
| December 31, 2023 | 0.376M |
| September 30, 2023 | 0.341M |
| June 30, 2023 | 0.457M |
| Date | Value |
|---|---|
| March 31, 2023 | 0.206M |
| December 31, 2022 | 0.238M |
| September 30, 2022 | 0.137M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
0.137M
Minimum
Sep 2022
0.582M
Maximum
Mar 2024
0.3339M
Average
0.341M
Median
Sep 2023
Revenue (Quarterly) Benchmarks
| Cormedix Inc | -- |
| Amicus Therapeutics Inc | 110.40M |
| Insmed Inc | 75.50M |
| Altimmune Inc | 0.005M |
| InfuSystems Holdings Inc | 32.00M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -26.79M |
| Total Expenses (Quarterly) | 24.74M |
| EPS Diluted (Quarterly) | -0.87 |
| Enterprise Value | 105.18M |
| Gross Profit Margin (Quarterly) | 86.25% |
| Profit Margin (Quarterly) | -4.60K% |
| Earnings Yield | -249.8% |
| Normalized Earnings Yield | -242.89 |